AstraZeneca has started a U.S. restructuring that includes cutting about 600 sales jobs in respiratory and immunology, according to reporting connected to internal planning. The change is tied to a broader three-year $1.5 billion savings program led by CEO Pascal Soriot. The affected teams are described as responsible for marketing products including Breztri and Airsupra, indicating a commercial recalibration rather than a shift limited to manufacturing or R&D. AstraZeneca did not comment on the restructuring details. For the biotech and pharma ecosystem, the move is a reminder that late-stage portfolio execution and cost discipline continue to shape resource allocation—even as companies emphasize reinvestment into new drug development.